News
Netgem Trading Summary : Over 30% growth of the subscriber base in 2021. Targeting over 500,000 subscribers by the end of 2022 (+ 40%).
Paris, January 25, 2022,
The total number of subscribers[1] to the Group's services reached 363,000 at the end of December 2021, up more than 30% over the year. Over the period gross profit grew by
Madvertise - 2022 FINANCIAL CALENDAR
Press Release Paris, January 21, 2022 – 6 PM
2022 FINANCIAL CALENDAR
Madvertise (Euronext Growth - FR0010812230 - ALMNG), the French AdTech company specializing in mobile centric digital
PRISMAFLEX INTERNATIONAL : Growth prospects confirmed in Q3: +24% on a like-for-like basis - Strong Printing activity
Significant points:
- Printing activity in Q3 attained its highest level on record to stand at €9.2 million (+37%) and confirms its growth dynamic.
- Hardware activity, slightly down over the
BD MULTIMEDIA : Acquisition of METACOLLECTOR
BD MULTIMEDIA announces the closing of an agreement to acquire METACOLLECTOR.
METACOLLECTOR is a platform for bringing public domain heritage art into the world of NFT.
METACOLLECTOR will soon
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2021 - IMPLEMENTATION OF A NEW EQUITY LINE
Lyon, 13 January 2022 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
DOLFINES (EX DIETSWELL) : DOLFINES pre-qualified by Saudi Aramco
Press Release – January 4, 2022
DOLFINES pre-qualified by Saudi Aramco for future tenders on inspection and Acceptance services contracts for its drilling rigs
After being audited by Saudi Aramco
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2022
Lyon, December 20, 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
GECI INTERNATIONAL : 2021-22 FIRST-HALF EARNINGS
2021-22 FIRST-HALF EARNINGS: Improvement in current operating income and financial structure further strengthened
During the Board meeting on December 16, 2021, the Directors reviewed and approved
FERMENTALG : NextStage AM acquires a stake in Fermentalg alongside Theodore H. Nixon and issues free share subscription warrants
Libourne – 16 December 2021 – Fermentalg (Euronext – FALG), a major French player in microalgae, has announced an equity investment from the NextStage AM investment fund in connection with the
PRISMAFLEX INTERNATIONAL : 2021-2022 half-year results: Upturn in activity and return to profits
2021-2022 six-month period analysis
- Activity up 26% driven by a strong upturn in Printing activity (+51% for the period), despite the on-going health crisis, notably in Q1.
- EBITDA positive at
GROUPE LDLC : OL GROUPE AND THE LDLC GROUP PRESENT THE LDLC ARENA
As part of the indoor arena project at OL Valley, OL Groupe and the LDLC Group are delighted to announce a naming agreement for OL Groupe's soon-to-be-built events arena in Décines. It will be
GROUPE LDLC : FIRST HALF 2021/2022 EARNINGS UP SHARPLY
- FIRST HALF CONSOLIDATED REVENUES OF €333.5M, UP 6%
- GROSS MARGIN RATE UP 1.2 PP TO 23.1%
- EBITDA UP 20% TO €30.7M - EBITDA MARGIN OF 9.2%
- 2021/2022 INTERIM DIVIDEND OF €0.80
Olivier de la
METabolic EXplorer announces the second process resulting from its ALTANØØVTM platform for the production of L-Valine.
METabolic EXplorer announces the second process resulting from its ALTANØØVTM platform for the production of L-Valine
- Patented technology
- Fermentation process validated at the pre-pilot stage
DOLFINES (EX DIETSWELL) : DOLFINES is actively pursuing the adaptation of its organization
Press Release – November 30, 2021
DOLFINES is actively pursuing the adaptation of its organization to meet the requirements of the energy transition market
- Legal separation of conventional and
Median Technologies Announces New Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization
Regulatory News:
Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules. New
GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
MADVERTISE ENTERS INTO EXCLUSIVE DISCUSSIONS WITH A VIEW TO ACQUIRING A STAKE IN VECTAURY
Press Release
Paris, 18 November 2021 – 6 pm
MADVERTISE ENTERS INTO EXCLUSIVE DISCUSSIONS
WITH A VIEW TO ACQUIRING A STAKE IN VECTAURY
Madvertise (Euronext Growth - FR0010812230 - ALMNG), the French
GenSight Biologics Reports Second Patient Case Showing Significant Visual Recovery after GS030 Optogenetic Treatment
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative
GECI INTERNATIONAL : 2021-22 FIRST-HALF REVENUES
GECI International, the Digital and Technology specialist, is reporting stable first-half revenues, in line with its target to return to profitability.
FIRST-HALF KEY DEVELOPMENTS
The Group's
Valbiotis meldet auf der Jahrestagung der American Heart Association (AHA) positive präklinische Ergebnisse für TOTUM•070 gegen Hypercholesterinämie
Valbiotis (Paris: ALVAL) (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und
Valbiotis Announces Positive Preclinical Results for TOTUM•070 in Hypercholesterolemia, Selected and Presented at the American Heart Association (AHA) Annual Meeting
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211114005021/en/
TOTUM•070 preclinical results AHA 2021 (Graphic
GenSight Biologics to Present New Clinical Data of LUMEVOQ® and GS030 Gene Therapies at the American Academy of Ophthalmology 2021 Meeting
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sensorion to present in person at “Jefferies London Healthcare Conference”
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
DOLFINES (EX DIETSWELL) : 2021 1st half results
Press Release – October 29, 2021
2021 1st HALF RESULTS
DOLFINES, an independent specialist in engineering and services for the renewable and conventional energy industry, announces its results for
AGROGENERATION : First Half 2021 Results
- Commodity price increases led to significant improvement in EBITDA
- Further reductions in administrative and financial costs contributed to a positive net result
- Good visibility on 2021 crop